Inside Human Genome Sciences’s Upcoming Earnings Release

Human Genome Sciences (NASDAQ:HGSI) will unveil its latest earnings on Tuesday, October 25, 2011. Human Genome Sciences is a commercially focused biopharmaceutical company.

Human Genome Sciences Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net loss of 39 cents per share, a wider loss from the year earlier quarter net loss of 22 cents. During the past three months, the average estimate has moved up from a loss of 43 cents. Between one and three months ago, the average estimate moved up. It has risen from a loss of 42 cents during the last month.

Past Earnings Performance: The company met estimates last quarter after falling short of forecasts in the prior two. Before reporting a loss of 42 cents per share in the second quarter to fall in line with expectations, the company beat estimates by 17 cents in the first quarter.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a decline of 26.6% in revenue from the year-earlier quarter to $37.3 million.

Analyst Ratings: Analysts are bullish on this stock with 13 analysts rating it as a buy, one rating it as a sell and two rating it as a hold.

A Look Back: In the second quarter, the company’s loss widened to a loss of a $80.7 million (42 cents a share) from a loss of $56.9 million (30 cents) a year earlier, meeting analyst expectations. Revenue fell 35.9% to $24.9 million from $38.8 million.

Key Stats:

Revenue has fallen for the past three quarters. Revenue fell 42.9% in first quarter from the year earlier and 59.8% in the fourth quarter of the last fiscal year.

Competitors to Watch: GlaxoSmithKline plc (NYSE:GSK), Immunomedics, Inc. (NASDAQ:IMMU), Teva Pharmaceutical Industries Ltd (NASDAQ:TEVA), Amgen, Inc. (NASDAQ:AMGN), Biogen Idec Inc. (NASDAQ:BIIB), AstraZeneca plc (NYSE:AZN), Merck & Co., Inc. (NYSE:MRK), Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX), Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), and Peregrine Pharmaceuticals (NASDAQ:PPHM).

Stock Price Performance: During July 26, 2011 to October 19, 2011, the stock price had fallen $7.29 (-34.3%) from $21.27 to $13.98. The stock price saw one of its best stretches over the last year between December 31, 2010 and January 12, 2011 when shares rose for nine-straight days, rising 12.9% (+$3.07) over that span. It saw one of its worst periods between April 27, 2011 and May 6, 2011 when shares fell for eight-straight days, falling 8% (-$2.38) over that span. Shares are down $9.91 (-41.5%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.